Creo Medical Group (LON:CREO) Reaches New 52-Week Low – Here’s Why

Creo Medical Group PLC (LON:CREO) reached a new 52-week low on Tuesday . The company traded as low as GBX 15.50 ($0.19) and last traded at GBX 15.95 ($0.20), with a volume of 449749 shares changing hands. The stock had previously closed at GBX 16.13 ($0.20).

Creo Medical Group Stock Performance

The firm has a market capitalization of £57.70 million, a P/E ratio of -266.67 and a beta of 0.86. The company has a 50-day moving average of GBX 21.46 and a 200-day moving average of GBX 28.49. The company has a current ratio of 3.24, a quick ratio of 2.19 and a debt-to-equity ratio of 29.96.

Insider Transactions at Creo Medical Group

In other Creo Medical Group news, insider Kevin Crofton bought 2,916,666 shares of the firm’s stock in a transaction that occurred on Monday, October 21st. The stock was acquired at an average price of GBX 24 ($0.30) per share, with a total value of £699,999.84 ($879,175.89). Also, insider Richard John Rees bought 98,000 shares of the stock in a transaction on Thursday, October 24th. The stock was acquired at an average price of GBX 20 ($0.25) per share, with a total value of £19,600 ($24,616.93). 22.43% of the stock is owned by corporate insiders.

About Creo Medical Group

Creo Medical Group PLC, through its subsidiaries, researches, develops, manufactures, and sells medical devices and instruments in the United Kingdom. It is developing CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with flexible, accurate, and highly controllable devices delivered through a flexible endoscope.